Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease

被引:27
|
作者
Koukias, Nikolaos
Buzzetti, Elena
Tsochatzis, Emmanuel A. [1 ,2 ]
机构
[1] Royal Free Hosp, UCL Inst Liver & Digest Hlth, Pond St, London NW3 2QG, England
[2] UCL, Pond St, London NW3 2QG, England
关键词
Non-alcoholic fatty liver disease; Fibrosis; Glucagon-like peptide 1; Leptin; Probiotics; INSULIN-RESISTANCE; METABOLIC SYNDROME; DOUBLE-BLIND; OBESITY; STEATOHEPATITIS; DYSBIOSIS; LIRAGLUTIDE; PATHWAYS; CAPACITY; CHILDREN;
D O I
10.23736/S0391-1977.16.02567-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and has a complex pathophysiology with multiple pathways of development and progression implicated. Intestinal hormones regulate multiple biological functions and may play a role in the pathogenesis of non alcoholic fatty liver disease (NAFLD) by affecting food intake, body weight and insulin resistance. Bacterial products can affect the secretion of these hormones and thus have an effect on metabolism. Gut microbiota are normally involved in the intestinal energy harvest and their role has been increasingly been implicated in the pathogenesis of obesity and NAFLD. The intestinal hormone pathways as well as the intestinal microbiota populations are potential therapeutic targets in the management of NAFLD. We review the evidence on the associations of the intestinal hormones and gut microbiota in the development, progression and treatment of NAFLD.
引用
收藏
页码:184 / 194
页数:11
相关论文
共 50 条
  • [21] Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota
    Wang, Tianjiao
    Guo, Xue-Kun
    Xu, Huji
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [22] Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis
    Alisi, Anna
    Ceccarelli, Sara
    Panera, Nadia
    Nobili, Valerio
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2012, 2 : 1 - 4
  • [23] Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice
    Le Roy, Tiphaine
    Llopis, Marta
    Lepage, Patricia
    Bruneau, Aurelia
    Rabot, Sylvie
    Bevilacqua, Claudia
    Martin, Patrice
    Philippe, Catherine
    Walker, Francine
    Bado, Andre
    Perlemuter, Gabriel
    Cassard-Doulcier, Anne-Marie
    Gerard, Philippe
    GUT, 2013, 62 (12) : 1787 - 1794
  • [24] Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?
    Knaapen, M.
    Kootte, R. S.
    Zoetendal, E. G.
    de Vos, W. M.
    Dallinga-Thie, G. M.
    Levi, M.
    Stroes, E. S.
    Nieuwdorp, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (04) : 331 - 337
  • [25] Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
    Scarpellini, E.
    Lupo, M.
    Iegri, C.
    Gasbarrini, A.
    De Santis, A.
    Tack, J.
    REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) : 141 - 147
  • [26] Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease
    De Gottardi, Andrea
    McCoy, Kathy D.
    JOURNAL OF HEPATOLOGY, 2011, 55 (06) : 1181 - 1183
  • [27] Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm
    Ghoshal, Uday C.
    Goel, Amit
    Quigley, Eamonn M. M.
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2020, 39 (01) : 9 - 21
  • [28] Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
    Long, Changrui
    Zhou, Xiaoyan
    Xia, Fan
    Zhou, Benjie
    BIOLOGY-BASEL, 2024, 13 (04):
  • [29] Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm
    Uday C. Ghoshal
    Amit Goel
    Eamonn M. M. Quigley
    Indian Journal of Gastroenterology, 2020, 39 : 9 - 21
  • [30] Intestinal microbiota and non alcoholic fatty liver disease
    Cassard, Anne-Marie
    Houron, Camille
    Ciocan, Dragos
    NUTRITION CLINIQUE ET METABOLISME, 2020, 34 (02): : 130 - 140